Key result
Pharmacologic VTE prophylaxis is not associated with reduced VTE or increased bleeding in chronic liver disease.
Why the study?
Does pharmacologic VTE prophylaxis reduce VTE or increase bleeding in hospitalized patients with chronic liver disease and elevated INR?
Cohort (n=300)
Does pharmacologic VTE prophylaxis reduce VTE or increase bleeding in hospitalized patients with chronic liver disease and elevated INR?
Absolute Event Rate: 7.6% vs 2.8%
p-value: p=0.07
Pharmacologic VTE prophylaxis in hospitalized patients with chronic liver disease and elevated INR did not significantly reduce VTE risk or increase major bleeding risk.
No takes yet. Share an insight, caveat, or question.
VTE ppx was not associated with lower VTE or higher bleeding in CLD; leaves open optimal use pending prospective trials.
Moorehead et al. (2015) conducted a cohort in Chronic liver disease (n=300). Pharmacologic VTE prophylaxis vs. No pharmacologic VTE prophylaxis was evaluated on Venous thromboembolism (VTE) (p=0.07). Pharmacologic VTE prophylaxis in hospitalized patients with chronic liver disease was not associated with a lower risk of VTE (7.6% vs 2.8%, P=0.07) or increased major bleeding (30% vs 34.3%, P=0.46).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: